VC fund profile · evidence-aware directory data
Forbion Growth Opportunities Fund IV stages, portfolio and investment profile
Later-stage biopharma investment vehicle in Europe and North America. October 6 2026 announcement disclosed €2.3B raised in aggregate with Forbion Ventures VIII; individual Growth IV allocation not disclosed. About 30 investments planned across BOTH funds.
Keep track of Forbion Growth Opportunities Fund IV
Save this profile to your VCT watchlist for a quick return.
Stage-based planning range
$100K–$1M
This is a planning range inferred from stage coverage, not a firm-disclosed check size.
Methodology: Stage bucket inferred from the rounds a fund leads or invests in.
No firm-specific check-size disclosure is recorded.
Investment stages
Leads: Not recorded
Participates: Not recorded
Sector focus
Not recorded
Geography
Netherlands
Founded Not recorded
Fund size / AUM
Not recorded
A separate fund-size evidence record is not yet available.
Portfolio in our directory
None yet
Linked startup profiles
Recent tracked investment
Not recorded
No dated round explicitly links this fund.
VCT investor research
Inside Forbion Growth Opportunities Fund IV's investment strategy
Independent, source-backed analysis of who the firm backs, deal evidence and whether it fits your stage.
Verified mandate and fund history
This vehicle is focused on growth financing for biotech therapies with substantial unmet clinical need. The combined €2.3B is not this vehicle's individual fund size. LPs mentioned in the combined announcement must not be assigned to this fund separately without evidence.
Source and uncertainty
Primary manager announcement: forbion.com. Amounts for other vehicles, firm AUM, LP commitments and targets are not interchangeable. Fund-level fees, returns and undisclosed allocations are not estimated.
Sources and verification
Dated company disclosures take priority over third-party databases. These sources support the analysis above.
Rounds they lead
Rounds they invest
Last verified: Not recorded. Check-size evidence is labeled by basis so planning estimates are not presented as firm disclosures.
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.